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Background: The cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) gene is expressed in the vascular
endothelium, which metabolizes arachidonic acid into 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic
acids (EETs). 20-HETE mediates cardiovascular homeostasis and growth response in vascular smooth muscle cells (VSMCs)
as well as the anti-platelet effect. EETs are potent endogenous vasodilators and inhibitors of vascular inflammation. This
study assessed the association between human CYP1A1 gene polymorphisms and coronary artery disease (CAD) in the
Uygur and Han in China.
Methods: Two independent case–control studies that recruited Han (389 patients with CAD and 411 controls) and Uygur
participants (293 patients with CAD and 408 controls) analyzed the relationship between CYP1A1 single nucleotide
polymorphisms (SNPs: rs4886605, rs12441817, rs4646422 and rs1048943) and CAD. All patients with CAD and controls
were genotyped for the four SNPs of CYP1A1 using TaqMan SNP genotyping assays.
Results: In the Uygur group, the distribution of the dominant model(CC vs CT + TT) of rs4886605 for the total sample and
the males was significantly different between CAD patients and control participants (P = 0.001 and P = 0.012, respectively),
The difference remained significant after a multivariate adjustment (P = 0.018, P = 0.015, respectively). The rs12441817 was
also associated with CAD in a dominant model for all participants (P = 0.003) and men (P = 0.012), and the difference
remained significant after a multivariate adjustment (P = 0.016, P = 0.002, respectively). However, we did not observe
differences in the Uygur females and Han group with regard to the allele frequency or genotypic distribution of
rs4886605 and rs12441817 between patients with CAD and control participants. Patients with CAD did not significantly
differ from the control participants with regard to the distributions of rs4646422 and rs1048943 genotypes, the dominant
model, the recessive model, or allele frequency in the Han and Uygur groups.
Conclusion: Both rs4886605 and rs12441817 SNPs of the CYP1A1 gene are associated with CAD in the Uygur population
of China.
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Coronary artery disease (CAD) accounts for nearly 40%
of all the Causes of mortality in developed countries
[1,2]. CAD is a complex, multifactorial and polygenic
disorder thought to result from the interaction between
an individual’s genetic makeup and various environmen-
tal factors [3]. Various gene variants are associated with
CAD [4,5].
Cytochrome P450 (CYP) is a super-family of cysteino-
heme enzymes that mediate the oxidative metabolism of
exogenous and endogenous molecules [6]. CYP enzymes
play an important role in maintaining cardiovascular health
because they catalyze the formation and/or metabolism of
several endogenous molecules, such as cholesterol, andro-
gens, estrogens, and several arachidonic acid metabolites,
that affect several cardiovascular functions [7,8]. Mounting
evidence demonstrates that CYP enzymes are involved in
the pathogenesis of CAD [9,10]. Polymorphisms of CYP
genes such as, CYP2C8, CYP2C9, CYP2J2 (epoxyeicosatrie-
noic acid[EET] synthesis) [11-13], CYP8A (prostacyclin
synthesis) [14], CYP11B2 (aldosterone synthesis) [15],
CYP17, and CYP19 (sex hormone synthesis) are related to
CAD [16]. The human gene cytochrome P450, family 1,
subfamily A, polypeptide 1 (CYP1A1) is expressed in the
vascular endothelium. In addition to the roles that CYP1A1
plays in metabolizing exogenous compounds such as poly-
cyclic aromatic hydrocarbons (PAHs) and aromatic amines
that increase the development of atherosclerotic le-
sions, it can metabolize arachidonic acid to terminal
20-hydroxyeicosatetraenoic acid (20-HETEs; 75–90%)
and, to a lesser extent, epoxyeicosatrienoic acids
(EETs; 5–7%) [17-19]. 20-HETE plays critical roles in
the regulation of cardiovascular, renal and pulmonary
homeostasis as well as the growth response in vascular
smooth muscle cells (VSMCs), cardiac function and
vascular tone [7]. In addition, 20-HETE has beneficial
anti-platelet effects and inhibits sodium reabsorption
in the renal tubules [20]. EETs generally have cardio-
protective effects [1].
Recently, several reports investigated the association
between CYP1A1 genetic polymorphisms and the risk of
CAD associated with cigarette smoking. Wang et al. [9],
Manfredi et al. [21], and Cornelis et al. [10], studied the
association between the CYP1A1 MspI polymorphism,
cigarette smoking, and the risk of CAD. They provided
inconsistent results. According to the physiological and
pathological mechanism of CYP1A1, the interaction be-
tween CYP1A1 and smoking can cause atherosclerosis.
furthermore, this gene can metabolize arachidonic acid
into 20-HETE and EETs, which can directly lead to ath-
erosclerosis [1]; However, few studies have excluded the
factors related to smoking and independently assessed
the relationship between CYP1A1 and coronary heart
disease.The present case–control study aimed to assess the as-
sociation between the human gene CYP1A1 and CAD ex-
cluding the risk factors related to smoking in the Uygur
and Han population who are two major ethnic groups in
Xinjiang, China. It can be further clarified physiological
and pathological mechanism that CYP1A1 can cause
CAD through Arachidonic acid metabolites such as 20-
HETE and EETs.
Materials and methods
Ethical approval of the study protocol
Written informed consent was obtained from all partici-
pants, who explicitly provided permission for all DNA ana-
lyses and the collection of relevant clinical data. The Ethics
Committee of the First Affiliated Hospital of Xinjiang
Medical University (Urumqi, China) approved this study,
which was conducted according to the standards of the
Declaration of Helsinki.
Participants
The participants were recruited from the Han and
Uygur population who live in the Xinjiang Uygur Au-
tonomous Region of China. All patients and controls
received differential diagnoses for chest pain at the Car-
diac Catheterization Laboratory of the First Affiliated
Hospital of Xinjiang Medical University between 2006
and 2013. Highly skilled physicians performed all coronary
angiography procedures using the Judkins approach [22].
At least two experienced imaging specialists interpreted
the coronary angiography findings, and the final CAD
diagnosis was made based on the angiography report.
We randomly sampled 293 Uygur patients with CAD
and 408 ethnically and geographically matched partici-
pants for the control group. In addition, we randomly
sampled 389 Han patients with CAD and 411 ethnically
and geographically matched participants for the control
group. CAD was defined as the presence of at least one
significant coronary artery stenosis of more than 50% lu-
minal diameter according to coronary angiography for all
groups. All control participants also underwent a coronary
angiogram and did not have coronary artery stenoses or
show clinical or electrocardiogram evidence of myocardial
infarction (MI) or CAD. Control participants were not
healthy individuals; some were diagnosed with hyperten-
sion, DM or hyperlipidemia. Thus, the control group was
exposed to the same risk factors of CAD; however, their
coronary angiogram results were normal. Data and infor-
mation regarding traditional coronary risk factors inclu-
ding hypertension, diabetes mellitus (DM), and smoking
were collected from all study participants. The diagnosis
of hypertension was established if patients were on antihy-
pertensive medication or if the mean of 3 measurements
of systolic blood pressure (SBP) was >140 mm Hg or dia-
stolic blood pressure (DBP) >90 mm Hg, respectively.
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World Health Organization (WHO). In addition, individ-
uals with a fasting plasma glucose of >7.0 mmol/L, or with
a history of diabetes or treatment with insulin were consi-
dered as diabetic. The smoking variable was dichotomized
as smokers (including current and ex-smokers) and non-
smokers. All patients with impaired renal function, malig-
nancy, connective tissue disease, valvular disease or chronic
inflammatory disease were excluded.
Blood collection and DNA extraction
Fasting blood samples drawn via venipuncture in the
catheter room were taken from all participants before
cardiac catheterization. The blood samples were drawn into
a 5-mL ethylene diamine tetraacetic acid (EDTA) tube and
centrifuged at 4000 × g for 5 min to separate the plasma
content. Genomic DNA was extracted from the peripheral
leukocytes using the standard phenol-chloroform method.
The DNA samples were stored at −80°C until use. For use,
the DNA was diluted to a concentration of 50 ng/μL.
Genotyping
CYP1A1 is located on chromosome 15q24. This gene
consists of approximately 6.068 kilobase pairs (kbp) and
contains seven exons that are separated by six introns













Figure 1 Structure of the human CYP1A1 gene. The gene consists of se
Filled boxes indicate the coding regions, while arrows indicate the locationCYP1A1 gene in the National Center for Biotechnology In-
formation SNP database (http://www.ncbi.nlm.nih.gov/
SNP). Using Haploview 4.2 and the HapMap phase II data-
base, we obtained four tag SNPs (rs4886605, rs12441817,
rs4646422 and rs1048943) using minor allele frequency
(MAF) of >0.1 and linkage disequilibrium patterns with
r2 ≥ 0.5 as a cut off. The position of SNP1, SNP2, SNP3 and
SNP4 (rs4886605, rs12441817, rs4646422 and rs1048943)
occurred in order of decreasing distance from the CYP1A1
gene 3′end (Figure 1). SNP1 (rs4886605) was located 8.037
kbp upstream from the start codon in exon 1; SNP2
(rs12441817) was located 7.863 kbp upstream from the
start codon in exon 1; SNP3 (rs4646422) was observed in
the exon 2 region of the gene; and SNP4 (rs1048943) was
observed in the exon 7 region of the gene. Genotyping was
undertaken using the TaqMan® SNP Genotyping Assay
(Applied Biosystems). The primers and probes used for the
TaqMan® SNP Genotyping Assays (ABI) were chosen based
on information on ABI’s website (http://appliedbiosystems.
com.cn/). Thermal cycling was conducted using the Ap-
plied Biosystems 7900HT Standard Real-Time PCR System.
Plates were read using the Sequence Detection Systems
(SDS) automation controller software v2.4 (ABI). PCR
amplification was performed using 2.5 μL of TaqMan Uni-
versa Master Mix, 0.15 μL probes and 1.85 ddH2O in a 6-











ven exons (boxes) separated by six introns (lines; intergenic regions).
s of single nucleotide polymorphism (SNPs). kbp, kilobase pairs.
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of 95°C for 15 s; and 60°C for 1 min. All 96-well plates were
read using Sequence Detection Systems (SDS) automation
controller software v2.4 (ABI).
Biochemical analyses
Serum concentrations of total cholesterol (TC), triglycer-
ide (TG), glucose (Glu), high-density lipoprotein choles-
terol (HDL-C), and low-density lipoprotein cholesterol
(LDL-C), were measured using standard methods at the
Central Laboratory of the First Affiliated Hospital of Xin
jiang Medical University.
Statistical analyses
All continuous variables (e.g., age, BMI, pulse, and choles-
terol levels) are presented as the means ± standard devi-
ation (S.D.). The differences between the CAD and control
groups were analyzed using independent-samples T-test.
The differences with regard to the frequencies of smoking,
hypertension, diabetes mellitus, and CYP1A1 genotypes
were analyzed using χ2 test or Fisher’s exact test where ap-
propriate. The Hardy-Weinberg equilibrium was assessed
using a χ2 analysis. Logistic regression analyses with effect
ratios (odds ratios [ORs] and 95% CIs) were used to assess
the contribution of the major risk factors. All statistical
analyses were performed using SPSS 16.0 for Windows
(SPSS Institute, Chicago, USA). P-value is 2-tailed, and P-
values of less than 0.05 were considered significant.
Results
Table 1 shows the clinical characteristics of the Han and
Uygur study participants. for total,men and women, The
plasma concentrations of Glu and LDL-C as well as the
rates of EH, DM, and smoking were all significantly higher
for patients with CAD than control participants in the
two ethnic population, and the plasma concentrations of
Glu was significantly higher only for total and men group.
BMI was significantly higher among total, men and
women patients with CAD than their control counterparts
in Uygur populations, and the plasma concentration of
TC was significantly higher for women group.
Tables 2 and 3 show the distribution of the genotypes
and alleles for the four CYP1A1 gene SNPs in the Han
and Uygur populations. The genotypic distribution of each
SNP matched the predicted Hardy-Weinberg equilibrium
values for both ethnicities (P > 0.05 for the CAD and con-
trol groups; data not shown).
The distribution of the SNP1 (rs4886605) genotypes
(P = 0.004) and the additive model (P = 0.027) signifi-
cantly differed between the CAD and control partici-
pants in the entire Uygur sample. The distribution of
SNP1 (rs4886605) alleles and the dominant model (CC
vs CT + TT) significantly differed between CAD and
control participants (alleles: P = 0.006 [total sample] andP = 0.021 [men]; dominant model: P = 0.001 [total sam-
ple] and P = 0.012 [men]). The T allele of rs4886605 was
found significantly more frequently in patients with CAD
than controls (total: 46.76% vs 39.09%; men: 46.43% vs
38.54%). The dominant model (CC vs CT + TT) of
rs4886605 was significantly lower among patients CAD
than controls (total: 25.60% vs 37.50%; men: 24.80% vs
36.10%). The distribution of SNP2 (rs12441817) genotypes
(P = 0.010) and the additive model (P = 0.048) significantly
differed between patients with CAD and controls for the
entire sample. The distribution of SNP2 (rs12441817) al-
leles and the dominant model (TT vs CC +CT) signifi-
cantly differed between patients CAD and controls
(alleles: P = 0.004 [total sample] and P = 0.013 [men];
dominant model: P = 0.003 [total sample] and P = 0.012
[men]). The C allele of rs12441817 was found significantly
more frequently in patients with CAD than control partic-
ipants (total: 40.27% vs 32.84%; men: 40.48% vs 32.20%).
The dominant model (TT vs CC + CT) of rs12441817 was
significantly lower among patients with CAD than control
participants (total: 34.10% vs 45.30%; men: 33.30% vs
45.40%). Moreover, significant differences were not ob-
served between patients with CAD and control partici-
pants (for total participants, males or females) in the
Uygur group with regard to the distributions of rs4646422
or rs1048943, the dominant model, the recessive model,
or allele frequency (P > 0.05). Similarly, significant differ-
ences were not observed between patients with CAD and
control participants (for total participants, males or fe-
males) within the Han group with regard to the distribu-
tions of rs4886605, rs12441817, rs4646422 or rs1048943,
the dominant model, the recessive model, or allele fre-
quency (P > 0.05).
Tables 4 and 5 show that multiple logistic regression ana-
lyses were performed with TG, TC, HDL, Glu, LDL-C, EH,
DM, and smoking because these variables are the major
confounding factors for CAD. Table 4: The significant dif-
ference observed with regard to rs4886605 was retained
after adjustment for TG, TC, HDL, Glu, LDL-C, EH, DM,
and smoking within the Uygur population (total partici-
pants: OR = 0.368, 95% confidence intervals [CI] = 0.185–
0.530, P = 0.018; men: OR = 0.350, 95% CI: 0.235–0.568,
P = 0.015). Table 5: The significant difference observed with
regard to rs12441817 was retained after multivariate adjust-
ment for TG, TC, HDL, Glu, LDL-C, EH, DM, and smok-
ing within Uygur population (total participants: OR = 0.253,
95% confidence intervals [CI] = 0.231–0.546, P = 0.016;
men: OR = 0.241, 95% CI = 0.132–0.478, P = 0.002).
Discussion
We found that variation in CYP1A1 gene is associated with
CAD in the Uygur population of China. After multivariate
adjustment, the associations between CYP1A1 gene poly-
morphisms with CAD were not modified. Our study is the
Table 1 Han and Uygur population characteristics of study participants
Han Uygur
Total Men Women Total Men Women
CAD Control P value CAD Control P value CAD Control P value CAD Control P value CAD Control P value CAD Control P value
Number (n) 389 411 294 224 95 187 293 408 210 205 83 203






















































































































































































































EH (%) 59.32 47.63 0.023* 62.31 43.34 <0.001* 57.27 51.22 0.031* 42.68 18.42 <0.001* 34.35 20.01 <0.001* 51 16.53 <0.001*
DM (%) 27.23 13.56 <0.001* 22.74 15.03 <0.001* 31.18 12.26 <0.001* 26.71 12.84 <0.001* 21.53 7.73 <0.001* 30.69 17.95 <0.001*
Smoke (%) 58.48 31.43 <0.001* 87.59 56.38 <0.001* 12.13 3.62 0.002* 33.15 17.97 <0.001* 63.73 34.9 <0.001* 5.63 1.23 0.023*
BMI, body mass index; Glu, glucose; TG, triglyceride; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; EH, essential hypertension; DM, diabetes mellitus. Continuous variables were





















Table 2 Genotype and allele distributions in the control subjects and patients with CAD in the Han population
Total Men Women
Variants CAD n (%) Control n (%) P Value CAD n (%) Control n (%) P Value CAD n (%) Control n (%) P Value
rs4886605(SNP1)
Genotyping
CC 79(20.3%) 96(23.4%) 58(19.7%) 51(22.8%) 21(22.1%) 45(24.1%)
CT 190(48.8%) 200(48.7%) 146(49.7%) 119(53.1%) 44(46.3%) 81(43.3%)
TT 120(30.8%) 115(28.0%) 0.494 90(30.6%) 54(24.1%) 0.248 30(31.6%) 61(32.6%) 0.881
Dominant model
CC 79(20.3%) 96(23.4%) 58(19.7%) 51(22.8%) 21(22.1%) 45(24.1%)
TT + CT 310(79.7%) 315(76.6%) 0.297 236(80.3%) 173(77.2%) 0.4 74(77.9%) 142(75.9%) 0.713
Recessive model
TT 120(30.8%) 115(28.0%) 0.494 90(30.6%) 54(24.1%) 0.248 30(31.6%) 61(32.6%)
CC + CT 269(69.2%) 296(72.0%) 0.373 204(69.4%) 170(75.9%) 0.102 65(68.4%) 126(67.4%) 0.86
Additive model
CT 190(48.8%) 200(48.7%) 146(49.7%) 119(53.1%) 44(46.3%) 81(43.3%)
CC + TT 199(51.1%) 211(51.3%) 0.959 148(50.3%) 105(46.9%) 0.434 51(53.7%) 106(56.7%) 0.632
Allele
C 348(44.7%) 392(47.7%) 262(44.6%) 221(49.3%) 86(45.3%) 171(45.7%)
T 430(55.3%) 430(52.3%) 0.236 326(55.4%) 227(50.7%) 0.127 104(54.7%) 203(54.3%) 0.918
rs12441817(SNP2)
Genotyping
CC 83(21.3%) 83(20.2%) 65(22.1%) 35(15.6%) 18(18.9%) 48(25.7%)
CT 205(52.7%) 199(48.4%) 154(52.4%) 121(54.0%) 51(53.7%) 78(41.7%)
TT 101(26.0%) 129(31.4%) 0.235 75(25.5%) 68(30.4%) 0.141 26(27.4%) 61(32.6%) 0.153
Dominant model
TT 101(26.0%) 129(31.4%) 0.235 75(25.5%) 68(30.4%) 0.141 26(27.4%) 61(32.6%)
CC + CT 288(74.0%) 282(68.6%) 0.09 219(74.5%) 156(69.6%) 0.222 69(72.6%) 126(67.4%) 0.367
Recessive model
CC 83(21.3%) 83(20.2%) 65(22.1%) 35(15.6%) 18(18.9%) 48(25.7%)
TT + CT 306(78.7%) 328(79.8%) 0.691 229(77.9%) 189(84.4%) 0.064 77(81.1%) 139(74.3%) 0.208
Additive model
CT 205(52.7%) 199(48.4%) 154(52.4%) 121(54.0%) 51(53.7%) 78(41.7%)
CC + TT 184(47.3%) 212(51.6%) 0.226 140(47.6%) 103(46.0%) 0.712 44(46.3%) 109(58.3%) 0.056
Allele
C 371(47.7%) 365(44.4%) 284(48.3%) 191(42.6%) 87(45.8%) 174(46.5%)
T 407(52.3%) 457(55.6%) 0.188 304(51.7%) 257(57.4%) 0.07 103(54.2%) 200(53.5%) 0.869
rs4646422(SNP3)
Genotyping
AA 270(69.4%) 286(69.6%) 206(70.1%) 152(67.9%) 64(67.4%) 134(71.7%)
AG 102(26.2%) 115(28.0%) 74(25.2%) 67(29.9%) 28(29.5%) 48(25.7%)
GG 17(4.4%) 10(2.4%) 0.294 14(4.8%) 5(2.2%) 0.187 3(3.2%) 5(2.7%) 0.759
Dominant model
AA 270(69.4%) 286(69.6%) 206(70.1%) 152(67.9%) 64(67.4%) 134(71.7%)
GG + AG 119(30.6%) 125(30.4%) 0.957 88(30.0%) 72(32.1%) 0.59 31(32.6%) 53(28.4%) 0.457
Recessive model
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Table 2 Genotype and allele distributions in the control subjects and patients with CAD in the Han population
(Continued)
GG 17(4.4%) 10(2.4%) 0.294 14(4.8%) 5(2.2%) 0.187 3(3.2%) 5(2.7%)
AA + AG 372(95.6%) 401(97.6%) 0.129 280(95.2%) 219(97.8%) 0.129 92(96.8%) 182(97.3%) 0.818
Additive model
AG 102(26.2%) 115(28.0%) 74(25.2%) 67(29.9%) 28(29.5%) 48(25.7%)
AA + GG 287(73.8%) 296(72.0%) 0.576 220(74.8%) 157(70.1%) 0.23 67(70.5%) 139(74.3%) 0.496
Allele
A 642(82.5%) 687(83.6%) 486(82.7%) 371(82.8%) 156(82.1%) 316(84.5%)
G 136(17.5%) 135(16.4%) 0.573 102(17.3%) 77(17.2%) 0.946 34(17.9%) 58(15.5%) 0.468
rs1048943(SNP4)
Genotyping
CC 20(5.1%) 17(4.1%) 15(5.1%) 8(3.6%) 5(5.3%) 9(4.8%)
CT 152(39.1%) 148(36.0%) 115(39.1%) 80(35.7%) 37(38.9%) 68(36.4%)
TT 217(55.8%) 246(59.9%) 0.47 164(55.8%) 136(60.7%) 0.45 53(55.8%) 110(58.8%) 0.888
Dominant model
TT 217(55.8%) 246(59.9%) 164(55.8%) 136(60.7%) 53(55.8%) 110(58.8%)
CC + CT 172(44.2%) 165(40.1%) 0.244 130(44.2%) 88(39.3%) 0.26 42(44.2%) 77(41.2%) 0.626
Recessive model
CC 20(5.1%) 17(4.1%) 15(5.1%) 8(3.6%) 5(5.3%) 9(4.8%)
TT + CT 369(94.9%) 394(95.9%) 0.499 279(94.9%) 216(96.4%) 0.402 90(94.7%) 178(95.2%) 0.87
Additive model
CT 152(39.1%) 148(36.0%) 115(39.1%) 80(35.7%) 37(38.9%) 68(36.4%)
CC + TT 237(60.9%) 263(64.0%) 0.371 179(60.9%) 144(64.3%) 0.429 58(61.1%) 119(63.6%) 0.671
Allele
C 192(24.7%) 182(22.1%) 145(24.7%) 96(21.4%) 47(24.7%) 86(23.0%)
T 586(75.3%) 640(77.9%) 0.231 443(75.3%) 352(78.6%) 0.223 143(75.3%) 288(77.0%) 0.645
CAD, coronary artery disease; SNP, single-nucleotide polymorphism.
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tween the human CYP1A1 gene and CAD in the Uygur
and Han populations in western China.
Several CYP enzyme families have been identified in the
heart, endothelium, and smooth muscle of blood vessels. A
link between the expression and activity of CYP and cardio-
vascular diseases (CVDs) such as hypertension, CAD, heart
failure, stroke, cardiomyopathy, and arrhythmia has been
established [7]. CYP1A1 polymorphisms can affect the me-
tabolism of arachidonic acid, thereby resulting in an altered
generating capacity of 20-HETE and EETs . 20-HETE have
5 physiological functions. First, 20-HETE increases the
intracellular calcium concentration and regulates the vaso-
constrictor responses of angiotensin II, vasopressin, and
norepinephrine [23-25]. Second, 20-HETE increases thymi-
dine incorporation in cells and regulates growth responses
in vascular smooth muscle cells (VSMCs) in response to
norepinephrine and angiotensin II [26-28]. Third, 20-HETE
inhibits Na + −K+ −ATPase activity and sodium transport
in the proximal tubule and is a key mediator of the long-
term control of arterial pressure [29-31]. Fourth, 20-HETEsignificantly contributes to ischemia -reperfusion injury,
and the exogenous administration of 20-HETE significantly
increases infarct size [32,33]. Fifth, 20-HETE inhibits plate-
let aggregation and the formation of thromboxane A2
(TxA2) during platelet activation [34]. in addition, CYP1A1
also metabolize arachidonic acid to EETs, which are potent
endogenous vasodilators, inhibitors of vascular inflamma-
tion, and possessors of potent vasodilatory and antiapopto-
tic and anti-thrombotic properties in the cardiovascular
system [35].
Several genetic polymorphisms have been reported in
the CYP1A1 gene including T6235C and T5639C in the
3′-flanking region, A4889G and C4887A at exon 7 [36].
Functional studies have revealed that these polymor-
phisms are associated with increased CYP1A1 activity
and/or inducibility [37]. Wang et al. [9] reported signifi-
cant association between CYP1A1 MspI polymorphism
and the risk of coronary artery disease(CAD) in cigarette
smoking. This increased risk was more evident among
light smokers with OR of 3.44, but not observed in non-
smokers or heavy smokers. Nevertheless, Manfredi et al.
Table 3 Genotype and allele distributions in control subjects and patients with CAD in the Uygur population
Total Men Women
Variants CAD n (%) Control n (%) P Value CAD n (%) Control n (%) P Value CAD n (%) Control n(%) P Value
rs4886605(SNP1)
Genotyping
CC 75(25.60%) 153(37.50%) 52(24.80%) 74(36.10%) 23(27.70%) 79(38.90%)
CT 162(55.30%) 191(46.80%) 121(57.60%) 104(50.70%) 41(49.40%) 87(42.90%)
TT 56(19.10%) 64(15.70%) 0.004* 37(17.60%) 27(13.20%) 0.036* 19(22.90%) 37(18.20%) 0.193
Dominant model
CC 75(25.60%) 153(37.50%) 52(24.80%) 74(36.10%) 23(27.70%) 79(38.90%)
TT + CT 218(74.40%) 255(62.50%) 0.001* 158(75.20%) 131(63.90%) 0.012* 60(72.30%) 124(61.10%) 0.073
Recessive model
TT 56(19.10%) 64(15.70%) 37(17.60%) 27(13.20%) 19(22.90%) 37(18.20%)
CC + CT 237(80.90%) 344(84.30%) 0.235 173(82.40%) 178(86.80%) 0.21 64(77.10%) 166(81.80%) 0.367
Additive model
CT 162(55.30%) 191(46.80%) 121(57.60%) 104(50.70%) 41(49.40%) 87(42.90%)
CC + TT 131(44.70%) 217(53.20%) 0.027* 89(42.40%) 101(49.30%) 0.159 42(50.60%) 116(57.10%) 0.313
Allele
C 312(53.24%) 497(60.91%) 225(53.57%) 252(61.46%) 87(52.41%) 245(60.34%)
T 274(46.76%) 319(39.09%) 0.006* 195(46.43%) 158(38.54%) 0.021* 79(47.59%) 161(39.66%) 0.081
rs12441817(SNP2)
Genotyping
CC 43(14.70%) 45(11.00%) 30(14.30%) 20(9.80%) 13(15.70%) 25(12.30%)
CT 150(51.20%) 178(43.60%) 110(52.40%) 92(44.90%) 40(48.20%) 86(42.40%)
TT 100(34.10%) 185(45.30%) 0.01* 70(33.30%) 93(45.40%) 0.034* 30(36.10%) 92(45.30%) 0.348
Dominant model
TT 100(34.10%) 185(45.30%) 70(33.30%) 93(45.40%) 30(36.10%) 92(45.30%)
CC + CT 193(65.90%) 223(54.60%) 0.003* 140(66.70%) 112(54.60%) 0.012* 53(63.90%) 111(54.70%) 0.154
Recessive model
CC 43(14.70%) 45(11.00%) 30(14.30%) 20(9.80%) 13(15.70%) 25(12.30%)
TT + CT 250(85.30%) 363(89.00%) 0.151 180(85.70%) 185(90.20%) 0.156 70(84.30%) 178(87.70%) 0.449
Additive model
CT 150(51.20%) 178(43.60%) 110(52.40%) 92(44.90%) 40(48.20%) 86(42.40%)
CC + TT 143(48.80%) 230(56.40%) 0.048* 100(47.60%) 113(55.10%) 0.126 43(51.80%) 117(57.60%) 0.368
Allele
C 236(40.27%) 268(32.84%) 170(40.48%) 132(32.20%) 66(39.78%) 136(33.50%)
T 350(59.73%) 548(67.16%) 0.004* 250(59.52%) 278(67.8%) 0.013* 100(60.22% 270(66.5%) 0.155
rs4646422(SNP3)
Genotyping
AA 251(85.7%) 350(85.80%) 178(84.80%) 177(86.30%) 73(88.00%) 173(85.20%)
AG 39(13.30%) 53(13.00%) 32(15.20%) 26(12.70%) 7(8.40%) 27(13.30%)
GG 3(1.00%) 5(1.20%) 0.963 0(0.00%) 2(1.00%) 0.319 3(3.60%) 3(1.50%) 0.291
Dominant model
AA 251(85.70%) 350(85.80%) 178(84.80%) 177(86.30%) 73(88.00%) 173(85.20%)
GG + AG 42(14.30%) 58(14.20%) 0.965 32(15.20%) 28(13.70%) 0.647 10(12.00%) 30(14.80%) 0.546
Recessive model
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Table 3 Genotype and allele distributions in control subjects and patients with CAD in the Uygur population
(Continued)
GG 3(1.00%) 5(1.20%) 0(0.00%) 2(1.00%) 3(3.60%) 3(1.50%)
AA + AG 290(99.00%) 403(98.80%) 0.803 210(100.00%) 203(99.00%) 0.243 80(96.40%) 200(98.50%) 0.275
Additive model
AG 39(13.30%) 53(13.00%) 32(15.20%) 26(12.70%) 7(8.40%) 27(13.30%)
AA + GG 254(86.70%) 355(87.00%) 0.901 178(84.80%) 179(87.30%) 0.453 76(91.60%) 176(86.70%) 0.248
Allele
A 541(92.32%) 753(92.28%) 388(92.38%) 380(92.68%) 153(92.17%) 373(91.87%)
G 45(7.68%) 63(7.72%) 0.977 32(7.62%) 30(7.31%) 0.869 13(7.83%) 33(8.13%) 0.906
rs1048943(SNP4)
Genotyping
CC 5(1.70%) 11(2.70%) 3(1.40%) 5(2.40%) 2(2.40%) 6(3.00%)
CT 85(29.00%) 112(27.50%) 63(30.00%) 54(26.30%) 22(26.50%) 58(28.60%)
TT 203(69.30%) 285(69.90%) 0.642 144(68.60%) 146(71.20%) 0.562 59(71.10%) 139(68.50%) 0.899
Dominant model
TT 203(69.30%) 285(69.90%) 144(68.60%) 146(71.20%) 59(71.10%) 139(68.50%)
CC + CT 90(30.70%) 123(30.20%) 0.872 66(31.40%) 59(28.70%) 0.557 24(28.90%) 64(31.60%) 0.664
Recessive model
CC 5(1.70%) 11(2.70%) 3(1.40%) 5(2.40%) 2(2.40%) 6(3.00%)
TT + CT 288(98.30%) 397(97.40%) 0.387 207(98.60%) 200(97.50%) 0.452 81(97.60%) 197(97.10%) 0.797
Additive model
CT 85(29.00%) 112(27.50%) 63(30.00%) 54(26.30%) 22(26.50%) 58(28.60%)
CC + TT 208(71.00%) 296(72.60%) 0.651 147(70.00%) 151(73.60%) 0.408 61(73.50%) 145(71.50%) 0.724
Allele
C 95(16.21%) 134(16.42%) 69(16.43%) 64(15.61%) 26(15.66%) 70(17.24%)
T 491(83.79%) 682(83.58%) 0.916 351(83.57%) 346(84.39%) 0.748 140(84.33%) 336(82.76%) 0.647
CAD, coronary artery disease; SNP, single-nucleotide polymorphism; *P < 0.05.
Zou et al. Lipids in Health and Disease 2014, 13:145 Page 9 of 12
http://www.lipidworld.com/content/13/1/145[21] found no significant association was observed be-
tween CYP1A1 MspI polymorphism and the presence of
CAD, or the number of significantly diseased vessels in
smokers. In agreement with this study, Cornelis et al. [10]
reported no significant association between CYP1A1Table 4 Multiple logistic regression analysis for CAD patients
Total
OR 95% CI P
Dominant model (CC vs CT + TT) 0.368 0.185–0.530 0.018
Smoking 8.29 5.365–12.846 <0.001
EH 6.651 3.957–10.952 <0.001
DM 1.524 0.949–2.495 0.284
Glu 1.352 1.241–1.482 <0.001
TG 1.347 1.273-1.638 0.251
TC 1.86 1.765-1.913 0.031
HDL 0.25 0.086-0.541 0.032
LDL 0.985 0.897–1.153 0.068
CAD, coronary artery disease; EH, essential hypertension; DM, diabetes mellitus; Glu
LDL, Low-density lipoprotein.polymorphism and the risk of myocardial infarction (MI)
in a study from Costa Rica. Chih-Ching Yeh et al. [38] re-
port CYP1A1*2C polymorphism, particularly in non-
smokers, may be associated with the individual susceptibil-
ity to CAD. From the above example, we have consideredand control subjects of Uygur population (rs4886605)
Men Women
OR 95% CI P OR 95% CI P
0.35 0.235–0.568 0.015 0.626 0.321–1.412 0.204
10.254 5.713–18.375 <0.001 0.232 0.039–1.825 0.262
9.81 4.94–20.513 <0.001 4.103 1.875–9.184 <0.001
1.902 0.926–3.854 0.087 0.95 0.358–2.243 0.757
1.348 1.183–1.517 <0.001 1.485 1.253–1.762 <0.001
1.384 1.169-1.615 0.015 1.653 1.321-1.859 0.021
1.846 1.713-1.917 0.013 1.89 1.694-2.132 0.027
0.231 0.069-0.182 0.021 0.516 0.285-0.930 0.012
0.924 0.897–1.358 0.21 0.427 0.203–0.947 0.135
, glucose; TG, triglyceride; TC, total cholesterol; HDL, high-density lipoprotein;
Table 5 Multiple logistic regression analysis for CAD patients and control subjects of Uygur population(rs12441817)
Total Men Women
OR 95% CI P OR 95% CI P OR 95% CI P
Dominant model (TT vs CT + CC) 0.253 0.231–0.546 0.016 0.241 0.132–0.478 0.002 0.723 0.273–1.523 0.362
Smoking 9.152 6.278–13.373 <0.001 11.286 6.325–19.178 <0.001 0.471 0.357–1.932 0.378
EH 7.435 3.835–10.637 <0.001 9.513 4.631–20.278 <0.001 5.158 1.532–9.259 <0.001
DM 1.338 0.754–2.269 0.376 1.723 0.785–3.832 0.173 0.632 0.209–2.371 0.952
Glu 1.432 1.341–1.573 <0.001 1.409 1.283–1.672 <0.001 1.538 1.327–1.849 <0.001
TG 1.475 1.348-1.721 0.032 1.469 1.258-1.732 0.016 1.727 1.486-2.327 0.011
TC 1.532 1.467-1.853 0.012 1.563 1.427-1.725 0.028 1.542 1.329-1.935 0.045
HDL 0.305 0.132-0.529 0.041 0.327 0.235-0.473 0.035 0.273 0.075-0.683 0.037
LDL 0.653 0.532–1.243 0.072 0.736 0.658–1.235 0.237 0.639 0.347–0.953 0.375
CAD, coronary artery disease; EH, essential hypertension; DM, diabetes mellitus; Glu, glucose; TG, triglyceride; TC, total cholesterol; HDL, high-density lipoprotein;
LDL, Low-density lipoprotein.
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account of polymorphisms of the CYP1A1 gene, Ethnic dif-
ferences, environmental factors. CYP1A1 might cause CAD
in some smokers or non-smokers. Their mechanisms of
CYP1A1 were different. CYP1A1 metabolites arachidonic
acid to 20-HETE, EETs, which cause CAD, in non-
smoking.
In this study, we hypothesized that variability in the
CYP1A1 gene might affect the risk of CAD through
CYP1A1 as an arachidonic acid epoxygenase enzyme in
nonsmoking. We genotyped four SNPs of this gene in
the Uygur and Han of China and assessed the associ-
ation between CYP1A1 polymorphisms and CAD using
a case–control analysis.
A significant difference was observed in the genotypic
distribution of SNP1 (rs4886605) between the patients
with CAD and controls within the full Uygur sample.
When men and women were analyzed separately, the T
allele frequency of rs4886605 was higher among men
with CAD than their control counterparts. No such dif-
ferences were observed among women. Thus, the risk of
CAD is increased with regard to the T allele of rs4886605
in men. The dominant model (CC vs CT +TT) was signifi-
cantly lower among patients with CAD than controls for
all participants and men; furthermore, this difference was
retained after adjusting for Glu, LDL-C, EH, DM, and
smoking (Table 4) using multiple logistic regression ana-
lyses. This finding indicated that the risk of CAD was de-
creased with the presence of the CC genotype of rs4886605
in Uygur men. In the full Uygur sample, a significant differ-
ence was observed in the genotypic distribution of SNP2
(rs12441817) between patients with CAD and controls.
When men and women were analyzed separately, the C
allele of rs12441817 was more frequency in men with CAD
than their control counterparts. No such differences were
observed among women. Thus, the risk of CAD was in-
creased with the appearance of the C allele in rs12441817
among men. The dominant model (TT vs CC+CT) wassignificantly lower among patients with CAD than controls
for all participants and men; furthermore, this difference
remained significant after adjusting for Glu, LDL-C, EH,
DM, and smoking (Table 5). This finding indicates that the
risk of CAD was decreased with the presence of the TT
genotype in rs12441817 among Uygur men.
We found associations between CAD and the CYP1A1
SNPs rs4886605 and rs12441817 among Uygur men. This
result might be caused by two reasons. First, it might be
because of sex hormones; for instance, estrogen protects
against oxidative stress and is vasoprotective [39-41]. The
vascular protective effects of estradiol are metabolized
into 2-hydroxyestradiol (2HE) by CYP1A1, and 2HE is
converted into 2-methoxyestradiol (2ME) by catechol-O-
methyl transferase. 2ME is antimitogenic, anti-angiogenic
and pro-apoptotic [42]. Second, it might be because of less
female samples. However, patients with CAD and controls
participants in the Han group did not significantly differ
with regard to the distributions of the rs4886605 and
rs12441817 genotypes, the dominant model, the recessive
model, or allele frequency (P > 0.05). This genetic differ-
ence associated with coronary heart disease might differ
across ethnic groups because of race,diet, or lifestyle.
Although SNP4 (rs1048943) was observed in the exon 7
region of the CYP1A1 gene and the polymorphisms caused
a loss of transcription factor binding at site Sp7, the syn-
thesis of 20-HETE and EETs was reduced. Chih-Ching Yeh
[38] showed that rs1048943 was independently associated
with a decreased risk of coronary artery disease in non-
smoker (OR = 0.32, 95% CIs = 0.15–0.70) in the Taiwanese
population, But they didn’t find the association between
rs1048943 and CAD in smoker. This study further indi-
cated some polymorphisms of CYP1A1 can cause CAD
through metabolism of 20-HETE and EETs excluding the
risk factors like smoking in different ethnic groups. Our
study was inconsistent with that study, showing no signifi-
cant association between rs1048943 and CAD among non-
smoking participants in the Uygur and Han of china.
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environment factors, might explain these results between
Chinese and Taiwanese population.
Few studies have focused on the association between
SNP3 (rs4646422) in the exon 2 and CAD . We did not
find significant differences between the patients with
CAD and controls with regard to the distributions of the
rs4646422 genotypes, the dominant model, the recessive
model, or allele frequency among the Han and Uygur
samples.
Our study has several limitations. On one hand, the
present study analyzed only a small sample data, More
studies will need to incorporate a large samplesize for
confirming the association. On the other hand, further
studies will need to be undertaken in order to clarify the
underlying molecular mechanism that polymorphism of
CYP1A1 gene was associated with CAD .
Conclusions
In conclusion, we found that rs4886605 and rs12441817
might be two novel polymorphisms of the CYP1A1 gene
associated with CAD in the Uygur population in China.
The CC genotype of rs4886605 and the TT genotype of
rs12441817 in the CYP1A1 gene might be protective genetic
markers of CAD, whereas the T allele of rs4886605 and
the C allele of rs12441817 might be genetic risk markers of
CAD in the Uygur population in China.
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